Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer

Xenidis, Nikolaos; Neanidis, K.; Amarantidis, Kyriakos; Dimopoulos, P.; Chamalidou, E.; Pitsiava, Dimitra; Tentes, Antonios-Apostolos K.; Chatzaki, Εkaterini; Karakitsos, Petros; Kakolyris, Stylianos

doi:10.1007/s00280-010-1284-2

Cited by 3 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mild neurotoxicity was observed in 5 patients and among them only 1(2.9%) was experiencing G2. By analysis other studies of OXL and VNR it is seen that toxicity profile is better and similar with most of the studies (4,27,(37)(38)(39)(40) and can be manageable with conservative treatments.…”

Section: Discussionsupporting

confidence: 55%

See 1 more Smart Citation

The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study

Mumtahana

Tiang

Zhang

et al. 2014

Int J Cancer Ther Oncol

View full text Add to dashboard Cite

Purpose: The main purpose of this study was to analyze the effects and tolerability of Oxaliplatin-Vinorelbine combination on Platinum-resistant epithelial ovarian carcinoma (EOC) patients. Methods: A single centered retrospective study comprising of 34 patients was conducted, and all 34 patients were treated with Vinorelbine 30 mg/m 2 on day 1 and 8 along with Oxaliplatin 100 mg/m 2 on day 1 of 3 weeks treatment cycle following progressive platinum-resistant EOC. Results: The combination showed an overall response rate (ORR) of 18% (95% CI, 4.4-31.6) where 2 (6%) patients had complete response and 4 (12%) patients had partial response. Stable disease was observed in 9 (26%) patients and progressive disease in 19 (56%) patients. Median diseases free survival, median relapse free survival and median time to progression was 17.05 months, 4.4 months, and 1.25 months, respectively. Hematological toxicities were mild; only 1 (2.9%) patient had G3 anemia and major non-hematological toxicities include nausea-vomiting, diarrhea, constipation, hepatotoxicity, fatigueness and alopecia, which are mainly limited to G1-G2 and reversible. Conclusion: The effect of this combination is moderate as a second line treatment of platinum resistant EOC; however, in comparison with other regimens of Vinorelbine and Oxaliplatin, the activity is substandard but the toxicity profile is well tolerable. Further multicenter evaluation is needed for the better understanding of the therapeutic efficacy of the combination.

show abstract

Section: Discussionsupporting

confidence: 55%

“…4,38 VNR (30mg/m 2 ) with Gemcitabine combination showed an ORR of 11% and SD of 24%, PD 65%. 39 However, OXL (100 mg/m 2 ) with Gemcitabine had the ORR of 37% and SD of 41%. 40 The median DFS of this regimen was 17.05 months (95% CI, -29.1 to 55.2) with an optimum of 21.3 months after a median follow up of 3.1 months.…”

Section: Discussionmentioning

confidence: 96%

The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study

Mumtahana

Tiang

Zhang

et al. 2014

Int J Cancer Ther Oncol

View full text Add to dashboard Cite

show abstract

“…For example, Ferrero et al described a response rate of 49% with gemcitabine and vinorelbine in platinum-sensitive patients [5], whereas Burger et al found a response rate of 29% in a mixed resistant-sensitive population [6]. Lower response rates are seen among platinum-resistant patients with response rates of 25% [7], 21% [8], 11% [9], and even 3% [10] with doxorubicin and gemcitabine, topotecan and oxaliplatin, gemcitabine and vinorelbine, and vinorelbine in various combinations and dosages, respectively. Regarding survival, palliative chemotherapy regimens achieve median overall survival rates after the first, second, third, fourth, and fifth relapse of 17.6 (95% CI 16.4–18.6), 11.3 (10.4–12.9), 8.9 (7.8–9.9), 6.2 (5.1–7.7) and 5.0 (3.8–10.4) months, respectively [11].…”

Section: Introductionmentioning

confidence: 99%

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

et al. 2017

View full text Add to dashboard Cite

BackgroundPrimary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy.Case presentationA 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m2 and doxorubicin 1.5 mg/m2 over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy.ConclusionsRepeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-3004-8) contains supplementary material, which is available to authorized users.

show abstract

Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10

Hong

Lee

Kim

et al. 2015

Gynecologic Oncology

View full text Add to dashboard Cite

Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer

Abstract: The vinorelbine plus gemcitabine combination at the present doses and schedule is a safe but ineffective regimen, and therefore, is not recommended as second-line and beyond treatment in patients with refractory ovarian cancer.

Cited by 3 publications

References 19 publications

The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study

The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10

Contact Info

Product

Resources

About